Wednesday, February 2, 2011

Some vaccines may protect children against cancer

Children who have had certain vaccines may be less likely to develop childhood cancer, especially one type of leukemia, according to a U.S. study.

The findings, published in The Journal of Pediatrics, showed that children born in areas where most children had been vaccinated for hepatitis B had about 20 percent lower odds of all types of childhood cancer than those born in areas where fewer were vaccinated.

In particular, those born in areas with high use both of polio vaccine and a vaccine series that included hepatitis B and polio, among other diseases, had 30 percent to 40 percent lower odds of getting acute lymphoblastic leukemia -- a type of leukemia that is most common in childhood.

Michael Scheurer, from the Baylor College of Medicine in Houston, Texas, and one of the study authors, warned that despite the apparent relationship, which should become clearer with future research, it's not a situation of "get your kids vaccinated and they won't get cancer."

Previous studies have shown mixed results. One theory is that some common infections may increase a child's risk of leukemia because of the effect they have on the developing immune system.

Vaccinations, theoretically, should then cut down on that cancer risk -- unless the vaccine itself closely enough mimics a natural infection.

Sunday, November 28, 2010

Vertex submits application for hepatitis C drug

Vertex Pharmaceuticals Inc. said today that it has completed the submission of a New Drug Application that seeks regulatory approval for telaprevir, a hepatitis C drug candidate with the potential to generate billions of dollars in annual revenue.

The submission includes a request to the US Food and Drug Administration to reduce the FDA’s review time from 10 months to six months, Cambridge-based Vertex said in a press release.

Sunday, November 21, 2010

Advances made in developing hepatitis C vaccine

Scientists are zeroing in on a promising vaccine to treat hepatitis C, an international symposium was told Friday in Montreal.

Three preliminary clinical trials in England are showing that a so-called therapeutic vaccine can boost the immune response in those infected with the hepatitis C virus.

Sunday, November 14, 2010

State DPH investigates hepatitis B outbreak suspected of causing five to die

The State Health Department (DHHS’ DPH) released findings on Friday on their investigation into GlenCare's assisted living facility in Wayne County. Health officials are attempting to locate the source of a hepatitis B outbreak in the North Carolina nursing home that is suspected of causing five deaths.

Wednesday, November 3, 2010

Learn how to protect yourself from hepatitis

A workshop on Hepatitis C, “A Serious Public Health Concern” is scheduled for 5:30 p.m. Nov. 17 at Terrebonne General Medical Center’s OutReach Center inside Southland Mall, 5953 W. Park Ave., Houma.

The workshop will present facts on this highly infectious disease that affects people of all ages in the U.S. and around the world and what you can do to protect yourself.

The event’s guest speaker is Dr. Khalid Moussa, a gastroenterologist at TGMC.

Wednesday, October 27, 2010

Hepatitis C increased risks for cerebrovascular-related death

Hepatitis C virus infection was an independent risk predictor of cerebrovascular deaths, indicating a biological gradient of cerebrovascular mortality with increasing serum hepatitis C virus RNA levels, researchers said.

The study included residents (n=23,665, aged 30 to 65 years) from a community-based prospective cohort who were enrolled from 1991 to 1992. Residents answered structured questionnaires and provided blood samples for various serological and biochemical tests at study entry. Researchers tested serum hepatitis C virus (HCV) RNA level and HCV genotype for participants seropositive for antibodies against HCV (anti-HCV).

Thursday, October 21, 2010

Anti-TNF Therapy Appears Safe in Patients With Hepatitis C and Inflammatory Bowel Disease: Presented at ACG

No immediate signals of adverse problems were observed among patients with hepatitis C virus (HCV) infection and inflammatory bowel disease (IBD) who were administered infliximab, researchers said here at the American College of Gastroenterology (ACG) 75th Annual Scientific Meeting.